title: Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.
authors.affiliation: Department of Internal Medicine, University of Innsbruck, Austria.
authors.forename: J
authors.initials: J
authors.lastname: Thaler
authors.forename: G
authors.initials: G
authors.lastname: Gastl
authors.forename: T
authors.initials: T
authors.lastname: Fluckinger
authors.forename: D
authors.initials: D
authors.lastname: Niederwieser
authors.forename: H
authors.initials: H
authors.lastname: Huber
authors.forename: H
authors.initials: H
authors.lastname: Seewann
authors.forename: H
authors.initials: H
authors.lastname: Silly
authors.forename: A
authors.initials: A
authors.lastname: Lang
authors.forename: C
authors.initials: C
authors.lastname: Abbrederis
authors.forename: H
authors.initials: H
authors.lastname: Gadner
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins